Orphans of best prevention

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 17, Issue 7, 2007, Pages 483-485

  Rubba, P ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT;

CARDIOVASCULAR DISEASE; COST BENEFIT ANALYSIS; ECONOMICS; EDITORIAL; HEALTH CARE COST; HUMAN; ITALY; RISK FACTOR; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; ITALY; RISK FACTORS; TREATMENT OUTCOME;

EID: 34547425812     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2007.04.001     Document Type: Editorial

References (15)

1. Operative recommendations at the conclusion of the 3rd National Conference on the Prevention of Cardiovascular Diseases. Ital Heart J 5 Suppl. 8 (2004 Nov) 122S-135S
2. Menotti A., Lanti M., Agabit-Rosei E., Carratelli L., Cavera G., Dormi A., et al. Riskard 2005. New tools for prediction of cardiovascular disease risk derived from Italian population studies. Nutr Metab Cardiovasc Dis 15 (2005) 426-440
3. Rubba P. Cardiovascular risk in the Mediterranean area is low: impact on clinical decision-making. Nutr Metab Cardiovasc Dis 15 (2005) 399-401
4. Montalcini T., Gorgone G., Federico D., Ceravolo R., Emanuele V., Sesti G., et al. Association of LDL cholesterol with carotid atherosclerosis in menopausal women affected by the metabolic syndrome. Nutr Metab Cardiovasc Dis 15 (2005) 368-372
5. Gotto Jr. A.M., Whitney E., Stein E.A., Shapiro D.R., Clearfield M., Weis S., et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention (AFCAPS/TexCAPS). Circulation 8 (2000) 477-484
6. Nakamura H., Arakawa K., Itakura H., Kitabatake A., Goto Y., Toyota T., et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial. Lancet 368 (2006) 1155-1163
7. Moon J.C., and Bogle R.G. Switching statins. BMJ 332 (2006) 1344-1345
8. Giampaoli S., Palmieri L., Mattiello A., and Panico S. Definition of high risk individuals to optimize strategies for primary prevention of cardiovascular diseases. Nutr Metab Cardiovasc Dis 15 (2005) 79-85
9. Thomas M., and Mann J. Increased thrombotic vascular event after change of statin. Lancet 352 (1998) 1830-1831
10. Ellner A. Rethinking prescribing in the United States. BMJ 327 (2003) 1397-1400
11. Krasuski R.A., Doeppenschmidt D., Henry J.S., et al. Conversion to atorvastatin in patients intolerant or refractory to simvastatin therapy: the CAPISH study. Mayo Clin Proc 80 9 (2005) 1163-1168
12. Raal F.J. A single-centre retrospective observational study to evaluate the change in total cholesterol and LDL cholesterol in hyperlipidaemic patient switched from atorvastatin to simvastatin. Cardiovasc J S Afr 15 (2004) 118-123
13. Stroes E.S., Koomans H.A., de Bruin T.W., and Rabelink T.J. Vascular function in the forearm of hypercholesterolemic patients off and on lipid-lowering medication. Lancet 346 8973 (1995) 467-471
14. Heeschen C., Hamm C.W., Lufs U., Snapinn S., Bohm M., White H.D., et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 105 12 (2002) 1446-1452
15. Antman E.M., and Ferguson J.J. Should evidence based proof of efficacy as defined for a specific therapeutic agent be extrapolated to encompass a therapeutic class of agent?. Circulation 108 (2003) 2604-2607